CLINICAL TRIAL

Omega-3 fatty acid ethyl esters (2 gram) for Colorectal Cancer

High Risk
Recruiting · 18+ · All Sexes · Kansas City, KS

This study is evaluating whether a specific type of fish oil may help reduce the risk of colorectal cancer.

See full description

About the trial for Colorectal Cancer

Eligible Conditions
Colorectal Neoplasms · Syndrome · Colorectal Neoplasms, Hereditary Nonpolyposis · Colorectal Carcinoma (CRC) · Lynch Syndrome

Treatment Groups

This trial involves 2 different treatments. Omega-3 Fatty Acid Ethyl Esters (2 Gram) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Omega-3 fatty acid ethyl esters (2 gram)
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Willing to have two colonoscopies and two biopsies, one at the beginning of the study and one at the end. show original
People who take Aspirin for chemoprevention must agree to stop taking it for at least four weeks before they enter the study, and they must continue to not take it throughout the trial period. show original
Female participants who are able to have children and male participants with partners who are able to have children must either practice abstinence or use two forms of contraception (hormonal and barrier) prior to entering the study and for the duration of their participation in the study show original
Participants with known Lynch Syndrome
Eastern Cooperative Oncology Group (ECOG) defines performance status as 0-1, which signifies that the individual is fully ambulatory and capable of all self-care activities. show original
The ability of the participant or their legally authorized representative to understand the study, and the participant or their legally authorized representative's willingness to sign a written informed consent. show original
The doctor is recommending that I have an elective endoscopy procedure show original
Adequate organ and marrow function
Men who might father a child must not take part in this study or donate sperm for 90 days after their last dose of treatment. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 12 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 12 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Omega-3 fatty acid ethyl esters (2 gram) will improve 1 primary outcome and 1 secondary outcome in patients with Colorectal Cancer. Measurement will happen over the course of 12 months.

Proportion of participants with treatment-related adverse events in each arm.
12 MONTHS
Measured by Common Terminology Criteria Adverse Events (CTCAE) V5.0
12 MONTHS
Retention rate of participants
12 MONTHS
Feasibility is defined as at least 80% retention rate
12 MONTHS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is colorectal cancer?

Around 4% of patients have colorectal cancer and most of them present with metastases at surgery. These are indications of a poorer outcome; however, 5-year survival rates are up to 80% if curative resection is feasible. The stage at the time of presentation is the most important prognostic factor.

Anonymous Patient Answer

What are the signs of colorectal cancer?

Although there may be a higher incidence of [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) in people with ulcerative colitis, patients should be encouraged to develop an awareness of the signs, since the colon is a key organ for cancer. Symptoms that can help in the early recognition of cancer may include colorectal bleeding or stool of irregular composition.

Anonymous Patient Answer

What are common treatments for colorectal cancer?

Very few people use these medications despite ample evidence and research showing that they are effective. Most people prefer surgery rather than any other treatment.

Anonymous Patient Answer

What causes colorectal cancer?

Environmental factors may contribute to [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) as they are to lung cancer. For a cancer to become malignant, it is likely that genetic lesions occur, some of which are due to environmental stresses. This may result in the dysregulation of the cell cycle and the activation of genes involved in cellular proliferation and survival in colorectal cancer. Smoking and alcohol add to the risk associated with these environmental risk factors.

Anonymous Patient Answer

How many people get colorectal cancer a year in the United States?

More than 5 million people in the United States are expected to be diagnosed with [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) in 2012, but more than 4 million would die from the disease. The lifetime risk of developing colorectal cancer is 3% in adults, and almost 9% in people with family history of cancer.\n

Anonymous Patient Answer

Can colorectal cancer be cured?

Colorectal resection for stage 3 or node metastases is curative in approximately 35% of cases. Patients with distant metastases have a worse survival and often do not progress as rapidly or reach stage 3 as those who underwent curative resections.

Anonymous Patient Answer

What is the average age someone gets colorectal cancer?

Age is a significant risk factor for [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer). It is important to know when and how many people are diagnosed with colorectal cancer and to implement cancer screening programs.

Anonymous Patient Answer

What are the latest developments in omega-3 fatty acid ethyl esters (2 gram) for therapeutic use?

Results from a recent clinical trial of this first study are encouraging and a significant effect was noticed in decreasing TCI, LDL, triacylglycerol and total cholesterol concentration. Omega-3 fatty acids could constitute a new class of drugs for the treatment and prevention of dyslipidemia. However, further studies are needed to confirm these efficacy and tolerance data.

Anonymous Patient Answer

What is the latest research for colorectal cancer?

There was a lot of new information presented at the ASCRS, which was a very beneficial meetings for all of us, the physicians. The new discoveries regarding the risk factors of colorectal cancer and the treatment of colorectal tumor were discussed by the doctors and other leading scientists in the field. At the end of the meeting a question and answer session was held. It was an open-minded forum to discuss the latest research data for colorectal cancer. It became a place to hear opinions and to learn things not just the facts. These facts are so important to understand. There is much more to know about colorectal cancer.

Anonymous Patient Answer

What does omega-3 fatty acid ethyl esters (2 gram) usually treat?

The benefits of consuming omega-3 fatty acid ethyl esters, which are commonly found in fish oil supplements, for treatment of colorectal disease should be weighed with safety concerns and must be assessed by a clinician with experience.

Anonymous Patient Answer

Have there been any new discoveries for treating colorectal cancer?

Oncology is a very dynamic field and there are ongoing discovery processes. The focus of treatment for [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) over the past century was on chemotherapy. This process culminated with the advent of chemotherapy, which was not associated with many of the side effects we are nowadays familiar with. This process culminated in the development of targeted drugs as well as antibody therapy. One of the most recent aspects of this field was the development of vaccines; these were not as successful as the previous cancer vaccines, such as the Sipuleucel-T-based vaccine and the Rotarix-derived vaccine.

Anonymous Patient Answer

Does colorectal cancer run in families?

Findings from a recent study suggest a role for genetic factors in the etiology of colorectal cancer with a hereditary susceptibility component, but the extent of the genetic contribution is not sufficient to explain the observed trends in frequency and age-adjusted incidence of colorectal cancer by race.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Colorectal Cancer by sharing your contact details with the study coordinator.